(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 February 2010 (25.02.2010)

PCT

(10) International Publication Number
WO 2010/021697 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 25/00* (2006.01)
C07K 14/715 (2006.01) *A61P 37/00* (2006.01)
C12N 5/12 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:
PCT/US2009/004711

(22) International Filing Date:
17 August 2009 (17.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/189,357 18 August 2008 (18.08.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and
(71) Applicants : **BELOUSKI, Shelley Sims** [US/US]; 4541 La Tuna Court, Camarillo, California 93012 (US). **GREEN, Larry L.** [US/US]; 464 Hill Street, San Francisco, California 94114 (US). **LIANG, Meina L.** [US/US]; 115 Glasgow Circle, Danville, California 94526 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GLADUE, Ronald P.** [US/US]; 83 Rowley Drive, Stonington, Connecticut 06378 (US). **KELLER, Bradley T.** [US/US]; 1861 Sweet Lake Court, Chesterfield, Missouri 63017 (US). **OGAWA, Shinji** [JP/US]; 15588 Hitchcock Road, Chesterfield, Missouri 63017 (US). **RAJPAL, Arvind** [US/US]; 519 Foerster Street, San Francisco, California 94127 (US). **TYLASKA, Laurie A.** [US/US]; 173 Branch Hill Road, Preston, Connecticut 06365 (US).

(74) Agents: **GUNNISON, Jane T.** et al.; Ropes & Gray LLP, 1211 Avenue of the Americas, New York, New York 10036-8704 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
16 September 2010

WO 2010/021697 A3

(54) Title: ANTIBODIES TO CCR2

(57) Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.